A case report of immune-related pneumonitis after combined treatment of non small cell lung cancer
Immunotherapy is the most promising method in the treatment of lung cancer, especially in connection with the rapidly growing development of monoclonal antibodies aimed at inhibiting immune checkpoints: anti-CTLA-4, anti-PD-1, anti-PD-L1. Classic immuno-mediated adverse events that occur with this m...
Main Authors: | E. S. Denisova, M. S. Ardzinba, K. K. Laktionov, D. I. Yudin, K. A. Sarantseva, G. V. Shcherbakova, N. V. Marinichenko |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Remedium Group LLC
2020-07-01
|
Series: | Медицинский совет |
Subjects: | |
Online Access: | https://www.med-sovet.pro/jour/article/view/5743 |
Similar Items
-
Immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: A review
by: Yuxuan Hao, et al.
Published: (2022-08-01) -
Pulse corticosteroid therapy in the treatment of steroid-refractory immune checkpoint inhibitor-related pneumonitis: Case report and review
by: Kuan-Chang Lai, et al.
Published: (2022-08-01) -
Risk factors for pneumonitis in advanced extrapulmonary cancer patients treated with immune checkpoint inhibitors
by: Yasuki Uchida, et al.
Published: (2022-05-01) -
A clinical case of immune-mediated pneumonitis after nivolumab in a patient with Burkitt lymphoma
by: K. I. Utesheva, et al.
Published: (2023-03-01) -
Comprehensive Pneumonitis Profile of Thoracic Radiotherapy Followed by Immune Checkpoint Inhibitor and Risk Factors for Radiation Recall Pneumonitis in Lung Cancer
by: Xiaotong Lu, et al.
Published: (2022-06-01)